RxDoctor Payments Data

Frederick Cook, MD

Ophthalmology · Rehoboth Beach, DENPI 1720076045

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for ophthalmology clinicians in DE, where the typical reported total is $1,099.

$537in general payments, 2019–2025

Across 27 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$97
  • Sun Pharmaceutical Industries Inc.$91
  • AbbVie$67
  • Bausch & Lomb Americas Inc.$46
  • Amgen$40
  • Genentech USA, Inc.$37
  • plus $159 from 7 others

What the payments were for

  • Food & beverage$537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$537 in reported general payments places this provider in the 30th percentile of 49 ophthalmology providers in Delaware.

See all ophthalmology providers in Delaware

Medicare billing

Part B allowed, 2024
$175,208
Medicare patients
1,006
Services billed
1,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost20$15,340
CombiganBrimonidine Tartrate/Timolol19$12,748
XiidraLifitegrast18$12,097
Travoprost35$11,557
Latanoprost525$9,127
Alphagan PBrimonidine Tartrate14$7,625
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$6,495
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat178$3,933
Brimonidine Tartrate35$2,903
Brinzolamide14$2,686
Timolol Maleate141$1,613
Dorzolamide Hcl32$640
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha28$404
ErythromycinErythromycin Base23$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$67$35,71353 claims
Bausch & Lomb Americas Inc.Xiidra$46$12,09718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 49 ophthalmology providers in Delaware.

Other ophthalmology in Rehoboth Beach

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →